The company reported net profit of Rs 1984.5 crore during the corresponding quarter of the previous year.
Sun Pharma board has declared an interim dividend of Rs. 5 per equity share for FY24. This is in addition to the interim dividend paid of Rs 8.5 already paid during the year.
Excluding exceptional items, the net profit for Q4FY24 grew 39% to Rs 2756.2 crore.
The exceptional items were related to an impairment charge on an acquired asset.
Revenue rose 10.1% YoY to Rs. 11813 crore in Q4FY24.
The earnings for interest, tax, depreciation and ammortisation (EBITDA) rose 8.3% to Rs. 3035 crore in Q4, and EBITDA margins declined 30 basis points YoY to 25.3%.
India formulation sales rose 10.2% YoY to Rs. 3707.8 crore in Q4FY24. India accounts for 31.4% of Sun Pharma sales.
Sun Pharma holds 8.5% market share and is ranked number one in the Rs. 1.97 lakh crore Indian pharmaceutical market as per AIOCD AWACS MAT March 2024 report.
In Q4FY24, the company launched 9 new products in the Indian market.
The US formulation including Taro sales were up 10.9% YoY to 3954.4 crore.
US formulation sales accounted for little over one-third of consolidated sales.
Global specialty sales stood at $271 million, up 11.1% YoY in Q4FY24.
While emerging markets formulation sales grew 10.8% YoY to Rs 2034.8 crore, rest-of-the-world (RoW) formulation sales grew 2.5% YoY to Rs 1629 crore.
R&D expenses rose 35.2% YoY to Rs 900 crore in Q4FY24.
